" />
Anti-TRAILR2/CDH17 Tetravalent Bispecific Antibody BI 905711 - CISMeF
Anti-TRAILR2/CDH17 Tetravalent Bispecific Antibody BI 905711NCIt concept
Preferred Label : Anti-TRAILR2/CDH17 Tetravalent Bispecific Antibody BI 905711;
NCIt synonyms : CDH17-targeting TRAILR2 Agonist BI 905711; Bi-specific Agent BI 905711;
NCIt definition : A tetravalent bispecific antibody targeting both the pro-apoptotic death receptor
tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 (TRAILR2;
death receptor 5; DR5) and cadherin-17 (CDH17), with potential pro-apoptotic and antineoplastic
activities. Upon administration of anti-TRAILR2/CDH17 tetravalent bispecific antibody
BI 905711, the antibody targets and binds to both TRAILR2 and CDH17, expressed on
tumor cells. Receptor clustering and activation of TRAILR2 induces apoptosis in CDH17-positive
cancer cells. Activation of TRAILR2 plays a key role in the induction of apoptosis.
CDH17-dependent clustering of TRAILR2 allows BI 905711 to selectively induce apoptosis
in CDH17-expressing tumor cells thereby increasing efficacy and decreasing liver toxicity.
CDH17 is overexpressed in a variety of cancer cell types while its expression is restricted
in normal liver tissue.;
Semantic type(s)